Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Veklury (remdesivir by Year
Veklury (remdesivir — COVID-19 antiviral) — Europe sales ($M) ($M)
Gilead Sciences Veklury (remdesivir: $151M in FY2025, down 46.8% from a year earlier.
Latest, FY2025
151
Period ended Dec 31, 2025
Change on a year earlier
-46.8%
284 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Veklury (remdesivir — COVID-19 antiviral) — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 151 | -46.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 284 | -30.4% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 408 | -41.9% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 702 | -35.9% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 1,095 | +80.4% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 607 | – | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Veklury (remdesivir ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/veklury-total-eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.